Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8412728 | 0.99 | ALDH1A1 (0.44) | ALDH1A1KDM4EHPGDKMT2AMEN1 | |
| SCHEMBL6357895 | 0.91 | RORC (0.49) | ALDH1A1KDM4EHPGDKMT2AMEN1 | |
| SCHEMBL6358821 | 0.88 | CTSK (0.44) | ALDH1A1KDM4EHPGDKMT2AMEN1 | |
| SCHEMBL6358099 | 0.88 | ALDH1A1 (0.39) | ALDH1A1KDM4EHPGDKMT2AMEN1 | |
| SCHEMBL6359207 | 0.86 | ALDH1A1 (0.39) | ALDH1A1KDM4EHPGDKMT2AMEN1 | |
| SCHEMBL6362871 | 0.86 | ALDH1A1 (0.39) | ALDH1A1KDM4EHPGDKMT2AMEN1 | |
| SCHEMBL7906816 | 0.86 | NPC1 (0.46) | ALDH1A1KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL6359212 | 0.85 | LTA4H (0.39) | ALDH1A1KDM4EHPGDKMT2AMEN1 | |
| SCHEMBL6362874 | 0.85 | LTA4H (0.39) | ALDH1A1KDM4EHPGDKMT2AMEN1 | |
| SCHEMBL8409698 | 0.85 | NPC1 (0.45) | ALDH1A1KDM4EKMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114920943-A | Group-modified macromolecular polymer, and preparation method and application thereof | 天津大学 | 2022-08-19 | — | — | CN | claimed |
| EP-4690456-A2 | VACUUM PACKAGING FOR PHOTONIC CRYSTALS AND METHODS THEREOF | Mesodyne Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4690455-A2 | SYSTEMS AND METHODS FOR PHOTONIC CRYSTAL INTEGRATION | Mesodyne Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4690454-A2 | PASSIVATION SYSTEMS AND METHODS FOR PHOTONIC CRYSTALS | Mesodyne Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4686718-A1 | SEPARATION OF POLYETHYLENE GLYCOLS FROM ETHOXYLATES | BASF SE (DE) | 2026-02-04 | — | — | EP | disclosed |
| EP-4686728-A1 | LOW CONTENT ETHOXYLATES OF POLYETHYLENE GLYCOLS | BASF SE (DE) | 2026-02-04 | — | — | EP | disclosed |
| EP-4686750-A1 | SEPARATION OF WATER FROM BETAINES | BASF SE (DE) | 2026-02-04 | — | — | EP | disclosed |
| US-12528999-B2 | Sustainable jet fuel and process | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2026-01-20 | — | — | US | disclosed |
| US-12503661-B2 | Additive compositions for fuel oils | INFINEUM INTERNATIONAL LIMITED (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250216071-A1 | RAPID MIXING SYSTEMS AND METHODS FOR FUEL BURNERS | MESODYNE INC. (US) | 2025-07-03 | — | — | US | disclosed |
| US-6894185-B2 | Substituted chiral allosteric hemoglobin modifiers | Allós Therapeutics, Inc. (US) | 2005-05-17 | — | — | US | disclosed |
| US-20030130523-A1 | Substituted chiral allosteric hemoglobin modifiers | ABRAHAM DONALD J (US) | 2003-07-10 | — | — | US | disclosed |
| US-6486342-B1 | Substituted chiral allosteric hemoglobin modifiers | VIRGINIA COMMONWEALTH UNIVERSITY | 2002-11-26 | — | — | US | disclosed |
| US-5927283-A | TREATING DISEASES INVOLVING OXYGEN DEFICIENCY, IN WOUND HEALING, AND IN RESTORING OXYGEN AFFINITY OF STORED BLOOD. | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1999-07-27 | — | — | US | disclosed |
| US-5872282-A | MAINTAIN OXYGEN AFFINITY IN BLOOD WHEN STORED | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1999-02-16 | — | — | US | disclosed |
| US-5731454-A | Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1998-03-24 | — | — | US | disclosed |
| US-5705521-A | Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogenic tumors | THE CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1998-01-06 | — | — | US | disclosed |
| US-5677330-A | THERAPY HYPOXIA, HYPOTHERMIA, ISCHEMIC, WOUNDS, ULCERS, TISSUE TRANSPLANTS, SESPIS | THE CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1997-10-14 | — | — | US | disclosed |
| US-5591892-A | CARBOXYALKOXYPHENYL SUBSTITUTED INDANES | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1997-01-07 | — | — | US | disclosed |
| US-5432191-A | Ring-substituted phenoxymethyl /or substituted methyl/ carboxylates | THE CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1995-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130523-A1 | Substituted chiral allosteric hemoglobin modifiers | HBZ, HBB, HBG2 | ALDH1A1 4454/4885KDM4E 809/4885HPGD 1583/4885 |
| US-12528999-B2 | Sustainable jet fuel and process | CYP2E1, ADH1C, PCCA | ALDH1A1 2234/4885KDM4E 3720/4885HPGD 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.